Illumina, Inc. (NASDAQ:ILMN) has earned a consensus rating of “Buy” from the twenty-five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $205.83.

ILMN has been the topic of several analyst reports. Barclays increased their price target on shares of Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 price target on the stock in a research report on Friday, October 27th. Canaccord Genuity restated a “buy” rating and issued a $230.00 target price (up previously from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Piper Jaffray Companies restated an “overweight” rating and issued a $226.00 target price (up previously from $202.00) on shares of Illumina in a research report on Monday, October 9th. Finally, Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd.

Illumina (NASDAQ:ILMN) traded up $2.98 during midday trading on Friday, hitting $217.65. 618,493 shares of the company traded hands, compared to its average volume of 954,357. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The firm has a market cap of $31,241.08, a price-to-earnings ratio of 62.57, a price-to-earnings-growth ratio of 3.53 and a beta of 0.79. Illumina has a twelve month low of $121.47 and a twelve month high of $230.72.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the business posted $0.97 EPS. equities research analysts predict that Illumina will post 3.75 earnings per share for the current year.

In related news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total transaction of $29,323.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $200.16, for a total transaction of $4,003,200.00. Following the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $107,921,468.16. The disclosure for this sale can be found here. Insiders have sold 166,150 shares of company stock valued at $34,767,331 in the last three months. 0.89% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisory Services Network LLC grew its holdings in Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the period. Penserra Capital Management LLC grew its holdings in Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after purchasing an additional 102 shares during the period. Dupont Capital Management Corp acquired a new stake in Illumina in the third quarter worth $153,000. Paradigm Asset Management Co. LLC grew its holdings in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares during the period. Finally, Patten Group Inc. grew its holdings in Illumina by 71.1% in the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock worth $172,000 after purchasing an additional 615 shares during the period. 91.75% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Illumina, Inc. (ILMN) Given Consensus Recommendation of “Buy” by Brokerages” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/08/illumina-inc-ilmn-given-consensus-recommendation-of-buy-by-brokerages.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.